MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412309 | Name: Carbocysteine lysine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Carbocysteine lysine dipeptide biochemical. Carbocysteine lysine is a mucoactive drug, has antioxidant and anti-inflammatory properties. Carbocysteine has been recently recognized as an effective and safe treatment for the long-term management of COPD, able to reduce the incidence of exacerbations and improve patient quality of life.

Chemical Structure

Carbocysteine lysine
Carbocysteine lysine
CAS#49673-81-6

Theoretical Analysis

MedKoo Cat#: 412309

Name: Carbocysteine lysine

CAS#: 49673-81-6

Chemical Formula: C11H23N3O6S

Exact Mass: 325.1308

Molecular Weight: 325.38

Elemental Analysis: C, 40.61; H, 7.13; N, 12.91; O, 29.50; S, 9.85

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Carbocysteine lysine; EINECS 256-425-9; UNII-1D1Y95PXXA
IUPAC/Chemical Name
L-Lysine, compound with S-(carboxymethyl)-L-cysteine (1:1)
InChi Key
SAGXGPWVLUSDSQ-RVZXSAGBSA-N
InChi Code
InChI=1S/C6H14N2O2.C5H9NO4S/c7-4-2-1-3-5(8)6(9)10;6-3(5(9)10)1-11-2-4(7)8/h5H,1-4,7-8H2,(H,9,10);3H,1-2,6H2,(H,7,8)(H,9,10)/t5-;3-/m00/s1
SMILES Code
N[C@@H](CCCCN)C(O)=O.N[C@@H](CSCC(O)=O)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 325.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Paone G, Lanata L, Saibene F, Toti S, Palermo P, Graziani C, Flore MC, Ramaccia M, Puglisi G. A prospective study of the effects of carbocysteine lysine salt on frequency of exacerbations in COPD patients treated with or without inhaled steroids. Eur Rev Med Pharmacol Sci. 2019 Aug;23(15):6727-6735. doi: 10.26355/eurrev_201908_18564. PMID: 31378916. 2: Brandolini L, Allegretti M, Berdini V, Cervellera MN, Mascagni P, Rinaldi M, Melillo G, Ghezzi P, Mengozzi M, Bertini R. Carbocysteine lysine salt monohydrate (SCMC-LYS) is a selective scavenger of reactive oxygen intermediates (ROIs). Eur Cytokine Netw. 2003 Jan-Mar;14(1):20-6. PMID: 12799210. 3: Biswas S, Hwang JW, Kirkham PA, Rahman I. Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease. Curr Med Chem. 2013;20(12):1496-530. doi: 10.2174/0929867311320120004. PMID: 22963552. 4: Pinamonti S, Venturoli L, Leis M, Chicca M, Barbieri A, Sostero S, Ravenna F, Daffonchio L, Novellini R, Ciaccia A. Antioxidant activity of carbocysteine lysine salt monohydrate. Panminerva Med. 2001 Sep;43(3):215-20. PMID: 11579333. 5: Asti C, Melillo G, Caselli GF, Daffonchio L, Hernandez A, Clavenna G, Omini C. Effectiveness of carbocysteine lysine salt monohydrate on models of airway inflammation and hyperresponsiveness. Pharmacol Res. 1995 Jun;31(6):387-92. doi: 10.1016/1043-6618(95)80094-8. PMID: 8685078. 6: Carpagnano GE, Resta O, Foschino-Barbaro MP, Spanevello A, Stefano A, Di Gioia G, Serviddio G, Gramiccioni E. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur J Pharmacol. 2004 Nov 28;505(1-3):169-75. doi: 10.1016/j.ejphar.2004.10.007. PMID: 15556150. 7: Caramia G, Gagliardini R, Ruffini E, Osimani P, Nobilini A. The management of cystic fibrosis with carbocysteine lysine salt: single-blind comparative study with ambroxol hydrochloride. J Int Med Res. 1995 Jul-Aug;23(4):284-93. doi: 10.1177/030006059502300409. PMID: 7589772. 8: Meyer G, Doppierio S, Daffonchio L, Cremaschi D. S-carbocysteine-lysine salt monohydrate and cAMP cause non-additive activation of the cystic fibrosis transmembrane regulator channel in human respiratory epithelium. FEBS Lett. 1997 Mar 3;404(1):11-4. doi: 10.1016/s0014-5793(97)00074-4. PMID: 9074627. 9: Mitchell SC, Steventon GB. Phenylalanine 4-monooxygenase: the "sulfoxidation polymorphism". Xenobiotica. 2020 Jan;50(1):51-63. doi: 10.1080/00498254.2019.1636419. Epub 2019 Jul 12. PMID: 31233370. 10: Braga PC, Allegra L, Rampoldi C, Ornaghi A, Beghi G. Long-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine-lysine to patients with chronic bronchitis. Respiration. 1990;57(6):353-8. doi: 10.1159/000195871. PMID: 2099568.

View History

FASN-IN-1

FASN-IN-1

Carbifene

Carbifene

SUN81928

SUN81928

BAY-297

BAY-297

BAY-069

BAY-069

BAY-241355

BAY-241355